search
Back to results

Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.

Primary Purpose

Crohn Disease, Recurrence, Azathioprine

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Azathioprine
Azathioprine in case of endoscopic recurrence
Ileocolonoscopy
Small bowel follow trough
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Crohn Disease

Eligibility Criteria

16 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Scheduled surgery for Crohn's disease (CD) with ileocolonic resection. Diagnosis of CD confirmed at least 4 months prior to surgery based on radiology and/or endoscopy.
  2. Having an increased risk for postoperative relapse for any of the following reasons: (1) active inflammatory disease with C-reactive protein level (CRP) elevated above 10 mg/L, or the use of antibiotics, steroids or biological therapy including infliximab for active ileal disease within 2 months before surgery which were administered for Crohn's disease and not for another unrelated intercurrent inflammatory or infectious disease; (2) perforating disease defined as the presence of entero-enteric or enterocutaneous fistulas or perivisceral abscess formation within 2 months before surgery. Perianal fistulizing disease will not be considered as an indication of perforating disease in the ileum or right-sided colon. (3) Previous ileo-colonic resection, (4) active smoking, (5) age below 30.
  3. Males and females 16-75 years old.
  4. Curative surgical resection. All macroscopically inflamed colonic segments (except for anorectal involvement) are to be removed at surgery. Stricturoplasties in small bowel segments not involving the anastomotic region are allowed.
  5. Patients able to start oral nutrition and oral therapy within 14 days from surgery.
  6. Patients able and willing to give written informed consent
  7. Women of childbearing potential should have a negative pregnancy test at inclusion.

Exclusion Criteria:

  1. Patients who only had strictureplasties or ileal/colonic resection without a new ileo-colonic anastomosis. Patients with ileorectal anastomosis.
  2. Patients with no increased risk of postoperative relapse as defined before.
  3. Patients with a known intolerance to azathioprine/6-mercaptopurine or with known homozygous thiopurine methyltransferase-low mutation.
  4. Patients in whom more than 100 cm of small bowel has been previously resected.
  5. Patients with active perianal disease or colorectal stenosis precluding ileocolonoscopy
  6. Patients with sepsis or other postoperative complications necessitating use of antibiotics for more than 14 days after surgery.
  7. Patients with liver test abnormalities (serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase, alkaline phosphatase, bilirubin > 2 ULN), leucopenia (<3000 white blood cell count /µL, <1500 neutrophils /µL), thrombopenia with < 50.000 platelets/mm3.
  8. Patients with severe renal, pulmonary or cardiac disease.
  9. Pregnant or lactating women.
  10. Ongoing alcohol or substance abuse.
  11. Ongoing or recent (within 6 months) infectious disease (viral hepatitis, tuberculosis, AIDS, Herpes zoster related disease).
  12. Known malignancy 5 years from surgery except for superficial epithelioma of the skin with curative resection.

Sites / Locations

  • Imelda Ziekenhuis
  • UZ Leuven
  • Univerzity Karlovy
  • Evangelismos Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Systematic azathioprine group

Endoscopy-driven azathioprine group

Arm Description

Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.

Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.

Outcomes

Primary Outcome Measures

Endoscopic remission
The proportion of patients with endoscopic remission (Rutgeerts' postoperative endoscopic score i0 or i1) at 102 weeks

Secondary Outcome Measures

Complete endoscopic remission
The percentage of patients with a Rutgeerts' score of i0 at 102 weeks
Absence of endoscopic relapse
The percentage of patients with a Rutgeerts' score of i0-i2 at 102 weeks
Clinical remission
The percentage of patients in clinical remission (Crohn's disease activity index, CDAI <150) at 102 weeks
Sustained clinical remission
Crohn's disease activity index, CDAI < 150 throughout the 102 weeks study period
Radiological remission
The percentage of patients with radiological remission at 102 weeks.

Full Information

First Posted
September 19, 2014
Last Updated
May 28, 2015
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
International organization for the study of inflammatory bowel disease (IOIBD)
search

1. Study Identification

Unique Protocol Identification Number
NCT02247258
Brief Title
Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.
Official Title
Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Terminated
Why Stopped
Slow recruitment
Study Start Date
October 2005 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
May 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
International organization for the study of inflammatory bowel disease (IOIBD)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to evaluate if in the prevention of postoperative recurrence of ileal Crohn's disease immediate initiation of azathioprine postoperatively is superior to delayed (6- 12 mths.) introduction of azathioprine upon disease recurrence assessed by endoscopic criteria. The primary endpoint, disease recurrence, encompasses symptomatic and surgical recurrence as well as severe endoscopic lesions at the final, 2 year, assessment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn Disease, Recurrence, Azathioprine, Prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
63 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Systematic azathioprine group
Arm Type
Active Comparator
Arm Description
Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
Arm Title
Endoscopy-driven azathioprine group
Arm Type
Active Comparator
Arm Description
Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
Intervention Type
Drug
Intervention Name(s)
Azathioprine
Intervention Description
See arm/group descriptions
Intervention Type
Drug
Intervention Name(s)
Azathioprine in case of endoscopic recurrence
Intervention Description
See arm/group descriptions
Intervention Type
Procedure
Intervention Name(s)
Ileocolonoscopy
Intervention Description
See arm/group descriptions
Intervention Type
Procedure
Intervention Name(s)
Small bowel follow trough
Intervention Description
See arm/group descriptions
Primary Outcome Measure Information:
Title
Endoscopic remission
Description
The proportion of patients with endoscopic remission (Rutgeerts' postoperative endoscopic score i0 or i1) at 102 weeks
Time Frame
Week 102
Secondary Outcome Measure Information:
Title
Complete endoscopic remission
Description
The percentage of patients with a Rutgeerts' score of i0 at 102 weeks
Time Frame
Week 102
Title
Absence of endoscopic relapse
Description
The percentage of patients with a Rutgeerts' score of i0-i2 at 102 weeks
Time Frame
Week 102
Title
Clinical remission
Description
The percentage of patients in clinical remission (Crohn's disease activity index, CDAI <150) at 102 weeks
Time Frame
Week 102
Title
Sustained clinical remission
Description
Crohn's disease activity index, CDAI < 150 throughout the 102 weeks study period
Time Frame
Week 102
Title
Radiological remission
Description
The percentage of patients with radiological remission at 102 weeks.
Time Frame
Week 102

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Scheduled surgery for Crohn's disease (CD) with ileocolonic resection. Diagnosis of CD confirmed at least 4 months prior to surgery based on radiology and/or endoscopy. Having an increased risk for postoperative relapse for any of the following reasons: (1) active inflammatory disease with C-reactive protein level (CRP) elevated above 10 mg/L, or the use of antibiotics, steroids or biological therapy including infliximab for active ileal disease within 2 months before surgery which were administered for Crohn's disease and not for another unrelated intercurrent inflammatory or infectious disease; (2) perforating disease defined as the presence of entero-enteric or enterocutaneous fistulas or perivisceral abscess formation within 2 months before surgery. Perianal fistulizing disease will not be considered as an indication of perforating disease in the ileum or right-sided colon. (3) Previous ileo-colonic resection, (4) active smoking, (5) age below 30. Males and females 16-75 years old. Curative surgical resection. All macroscopically inflamed colonic segments (except for anorectal involvement) are to be removed at surgery. Stricturoplasties in small bowel segments not involving the anastomotic region are allowed. Patients able to start oral nutrition and oral therapy within 14 days from surgery. Patients able and willing to give written informed consent Women of childbearing potential should have a negative pregnancy test at inclusion. Exclusion Criteria: Patients who only had strictureplasties or ileal/colonic resection without a new ileo-colonic anastomosis. Patients with ileorectal anastomosis. Patients with no increased risk of postoperative relapse as defined before. Patients with a known intolerance to azathioprine/6-mercaptopurine or with known homozygous thiopurine methyltransferase-low mutation. Patients in whom more than 100 cm of small bowel has been previously resected. Patients with active perianal disease or colorectal stenosis precluding ileocolonoscopy Patients with sepsis or other postoperative complications necessitating use of antibiotics for more than 14 days after surgery. Patients with liver test abnormalities (serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase, alkaline phosphatase, bilirubin > 2 ULN), leucopenia (<3000 white blood cell count /µL, <1500 neutrophils /µL), thrombopenia with < 50.000 platelets/mm3. Patients with severe renal, pulmonary or cardiac disease. Pregnant or lactating women. Ongoing alcohol or substance abuse. Ongoing or recent (within 6 months) infectious disease (viral hepatitis, tuberculosis, AIDS, Herpes zoster related disease). Known malignancy 5 years from surgery except for superficial epithelioma of the skin with curative resection.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gert Van Assche, MD PhD
Organizational Affiliation
UZ Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
Imelda Ziekenhuis
City
Bonheiden
Country
Belgium
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Univerzity Karlovy
City
Prague
Country
Czech Republic
Facility Name
Evangelismos Hospital
City
Athens
Country
Greece

12. IPD Sharing Statement

Citations:
PubMed Identifier
25926532
Citation
Ferrante M, Papamichael K, Duricova D, D'Haens G, Vermeire S, Archavlis E, Rutgeerts P, Bortlik M, Mantzaris G, Van Assche G; International Organization for Study of Inflammatory Bowel Diseases. Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. J Crohns Colitis. 2015 Aug;9(8):617-24. doi: 10.1093/ecco-jcc/jjv076. Epub 2015 Apr 29.
Results Reference
derived

Learn more about this trial

Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.

We'll reach out to this number within 24 hrs